4- (3- aminopyrrolidin- 1- yl)- 6- isopropylpyrimidin- 2- ylamine

07/01/2014 - "Due to a carryover effect of JNJ 39758979, only treatment period 1 was used for pruritus-related evaluations. "
01/01/2017 - "JNJ 39758979 advanced into human clinical studies and showed efficacy in reducing experimental pruritus and in patients with atopic dermatitis. "
07/01/2014 - "In conclusion, JNJ 39758979 was effective in inhibiting histamine-induced pruritus in healthy subjects. "
07/01/2014 - "The histamine H₄ receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects."
07/01/2014 - "A clinical study was conducted to evaluate the safety and efficacy of the H4R antagonist, JNJ 39758979 [(R)-4-(3-amino-pyrrolidin-1-yl)-6-isopropyl-pyrimidin-2-ylamine], on histamine-induced pruritus in healthy subjects. "

01/01/2017 - "JNJ 39758979 advanced into human clinical studies and showed efficacy in reducing experimental pruritus and in patients with atopic dermatitis. "
03/27/2014 - "This report discloses the discovery and SAR of a series of 6-alkyl-2-aminopyrimidine derived histamine H4 antagonists that led to the development of JNJ 39758979, which has been studied in phase II clinical trials in asthma and atopic dermatitis. "

02/01/2015 - "Safety, including adverse events (AE), was comparable between JNJ-39758979 and placebo with the exception of two patients (both receiving JNJ-39758979 300 mg) with serious AE of neutropenia, leading to premature study discontinuation. "

03/27/2014 - "This report discloses the discovery and SAR of a series of 6-alkyl-2-aminopyrimidine derived histamine H4 antagonists that led to the development of JNJ 39758979, which has been studied in phase II clinical trials in asthma and atopic dermatitis. "

07/01/2014 - "Adverse eventss reported in >1 patient with JNJ 39758979 were headache (9%) and nausea (13%). "